Advancium Paid Aileron Non-Refundable Fee for Exclusive Option to Acquire ALRN-6924 and Related Assets >ALRN

Dow JonesOct 31 07:40 ET

Advancium Will Evaluate ALRN-6924 as a Potential Therapy for Retinoblastoma

Dow JonesOct 31 07:32 ET

Aileron Therapeutics: Agreement Marks First of Its Kind for Advancium, a Public Charity Launched by Deerfield

Dow JonesOct 31 07:31 ET

Express News | Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of Alrn-6924 for Retinoblastoma

ReutersOct 31 07:30 ET

Reported Saturday, Aileron Therapeutics To Present Phase 1b Trial Data On LTI-03 For Idiopathic Pulmonary Fibrosis At 22nd Lung Fibrosis Colloquium

BenzingaOct 14 03:27 ET

Aileron Therapeutics Completes Enrollment for Phase 1b IPF Drug Trial, Topline Data Expected Soon

BenzingaSep 23 07:37 ET